Pharmaceutical - Anti-virals, Gilead Sciences

Filter

Popular Filters

1 to 25 of 43 results

Bristol-Myers’ hep C drug Daklinza approved in Europe

Bristol-Myers’ hep C drug Daklinza approved in Europe

27-08-2014

US pharma major Bristol-Myers Squibb says that the European Commission has approved Daklinza (daclatasvir),…

Anti-viralsBristol-Myers SquibbDaklinzaEuropeGilead SciencesPharmaceuticalRegulationSovaldi

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

New treatments to boost hepatitis C market to $19.2 billion by 2016

New treatments to boost hepatitis C market to $19.2 billion by 2016

24-06-2014

The launch of interferon-free regimens is expected to boost the hepatitis C market from $2.9 billion…

Anti-viralsAntiviralsBusiness FinanceCytokinesDatamonitorGilead SciencesGlobalMajorMarkets & MarketingPharmaceuticalSovaldi

Arrival of new hepatitis C therapies will increase the drug-treated population in China

Arrival of new hepatitis C therapies will increase the drug-treated population in China

19-06-2014

China’s market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated…

Anti-viralsasunaprevirBristol-Myers SquibbChinadanoprevirGilead SciencesJanssenMarkets & MarketingOlysioPharmaceuticalRocheSovaldi

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

New drug combo cures toughest cases of hepatitis C, hints to future injection-free therapies

16-01-2014

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans…

Anti-viralsBristol-Myers SquibbdaclatasvirGilead SciencesPharmaceuticalResearchsofosbuvir

Brazil National Health System coverage of and access to HIV drugs

Brazil National Health System coverage of and access to HIV drugs

27-12-2013

Brazil’s National Health System (SUS) currently provides coverage for 22 drugs that are distributed…

AbbVieAnti-viralsAtriplaBrazilEvipleraGilead SciencesGlaxoSmithKlineHealthcareKaletra TabletsMarkets & MarketingPharmaceuticalSouth AmericaTriovirTruvadaViread

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir

03-11-2013

Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

EMA advises on compassionate use of sofosbuvir for hepatitis C

EMA advises on compassionate use of sofosbuvir for hepatitis C

25-10-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given an…

Anti-viralsEuropeGilead SciencesPharmaceuticalRegulationsofosbuvir

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

AHF claims victory over FDA in HIV prevention drug case

08-08-2013

The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting

24-04-2013

Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

AHF demands FDA reversal on use of Gilead's HIV prevention pill for women

06-03-2013

Citing another failed clinical trial in women of the use of Gilead Sciences' (Nasdaq: GILD) AIDS drug…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationResearchTruvada

1 to 25 of 43 results

Back to top